BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23296022)

  • 21. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
    Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
    Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
    Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.
    Hallas C; Preukschas M; Tiemann M
    Leuk Res; 2019 Jan; 76():107-111. PubMed ID: 30360939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
    Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
    Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
    N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.
    Ramis-Zaldivar JE; Gonzalez-Farré B; Balagué O; Celis V; Nadeu F; Salmerón-Villalobos J; Andrés M; Martin-Guerrero I; Garrido-Pontnou M; Gaafar A; Suñol M; Bárcena C; Garcia-Bragado F; Andión M; Azorín D; Astigarraga I; Sagaseta de Ilurdoz M; Sábado C; Gallego S; Verdú-Amorós J; Fernandez-Delgado R; Perez V; Tapia G; Mozos A; Torrent M; Solano-Páez P; Rivas-Delgado A; Dlouhy I; Clot G; Enjuanes A; López-Guillermo A; Galera P; Oberley MJ; Maguire A; Ramsower C; Rimsza LM; Quintanilla-Martinez L; Jaffe ES; Campo E; Salaverria I
    Blood; 2020 Jan; 135(4):274-286. PubMed ID: 31738823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
    Bea S; Zettl A; Wright G; Salaverria I; Jehn P; Moreno V; Burek C; Ott G; Puig X; Yang L; Lopez-Guillermo A; Chan WC; Greiner TC; Weisenburger DD; Armitage JO; Gascoyne RD; Connors JM; Grogan TM; Braziel R; Fisher RI; Smeland EB; Kvaloy S; Holte H; Delabie J; Simon R; Powell J; Wilson WH; Jaffe ES; Montserrat E; Muller-Hermelink HK; Staudt LM; Campo E; Rosenwald A;
    Blood; 2005 Nov; 106(9):3183-90. PubMed ID: 16046532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.
    Yuan J; Wright G; Rosenwald A; Steidl C; Gascoyne RD; Connors JM; Mottok A; Weisenburger DD; Greiner TC; Fu K; Smith L; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Ott G; Vose JM; Staudt LM; Chan WC;
    Am J Surg Pathol; 2015 Oct; 39(10):1322-30. PubMed ID: 26135560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.
    Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.